Actelion says wins Japanese approval for heart and lung drug

ZURICH (Reuters) - Actelion said on Thursday the Japanese health regulator approved Opsumit, its new treatment for pulmonary arterial hypertension (PAH). The Swiss firm's drug has already won approval in the United States and Europe. (Reporting By Katharina Bart; Editing by Thomas Atkins)



via Health News Headlines - Yahoo News http://ift.tt/1BqHOjk